Faculty Opinions recommendation of B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis.

Author(s):  
Kenneth Tung
2006 ◽  
Vol 203 (2) ◽  
pp. 349-358 ◽  
Author(s):  
Shiguang Yu ◽  
Prasanta K. Maiti ◽  
Melissa Dyson ◽  
Renu Jain ◽  
Helen Braley-Mullen

Wild-type (WT) NOD.H-2h4 mice develop spontaneous autoimmune thyroiditis (SAT) when given 0.05% NaI in their drinking water, whereas B cell–deficient NOD.H-2h4 mice are SAT resistant. To test the hypothesis that resistance of B cell–deficient mice to SAT was due to the activity of regulatory CD4+CD25+ T (T reg) cells activated if autoantigen was initially presented on non–B cells, CD25+ T reg cells were transiently depleted in vivo using anti-CD25. B cell–deficient NOD.H-2h4 mice given three weekly injections of anti-CD25 developed SAT 8 wk after NaI water. Thyroid lesions were similar to those in WT mice except there were no B cells in thyroid infiltrates. WT and B cell–deficient mice had similar numbers of CD4+CD25+Foxp3+ cells. Mice with transgenic nitrophenyl-specific B cells unable to secrete immunoglobulin were also resistant to SAT, and transient depletion of T reg cells resulted in severe SAT with both T and B cells in thyroid infiltrates. T reg cells that inhibit SAT were eliminated by day 3 thymectomy, indicating they belong to the subset of naturally occurring T reg cells. However, T reg cell depletion did not increase SAT severity in WT mice, suggesting that T reg cells may be nonfunctional when effector T cells are activated; i.e., by autoantigen-presenting B cells.


2007 ◽  
Vol 178 (11) ◽  
pp. 6840-6848 ◽  
Author(s):  
Kutlu G. Elpek ◽  
Chantale Lacelle ◽  
Narendra P. Singh ◽  
Esma S. Yolcu ◽  
Haval Shirwan

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 759-759
Author(s):  
June H Myklebust ◽  
Jonathan M Irish ◽  
Roch Houot ◽  
Joshua Brody ◽  
Debra K Czerwinski ◽  
...  

Abstract Abstract 759 Introduction: Tumor infiltrating T cells present within biopsy specimens of human B cell non-Hodgkin's lymphomas (NHL) provide a valuable opportunity to examine immune system function in the presence of cancer. We recently used flow cytometry to characterize signaling in subpopulations of tumor samples from patients with follicular lymphoma (FL). In FL, we identified a novel lymphoma cell subset with impaired B cell antigen receptor (BCR) signaling, the prevalence of which correlated with adverse clinical outcome. Here, we turned our attention to signaling differences in subsets of the tumor-infiltrating T cells from FL and two other NHLs, diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Signaling differences that distinguish the tumor infiltrating T cells from each malignancy might be expected to be a reflection of the specific disease microenvironment, whereas T cell signaling differences distinguishing cases of the same malignancy might be related to the biology of each patient's tumor. Methods: Single cell flow cytometry measurements of signaling were acquired for samples of DLBCL (N=13), MCL (N=20), and FL (N=14). Phosphorylation of 14 signaling proteins was measured under 12 stimulation conditions in every cell, including lymphoma B cells and tumor-infiltrating T cells within the same specimen. Stimulation conditions included those that were B cell specific (BCR crosslinking, CD40 ligand), T cell specific (IL-7), and those that stimulated both B and T cells (IL-4, IL-10, IL-21, PMA + ionomycin, and IFN-γ). Results: Striking differences were observed in the signaling responses of tumor infiltrating T cells. T cells infiltrating FL patient samples showed significantly lower responses to cytokines where signal transduction is mediated by the common γ chain receptor. Specifically, we observed significant lower induction of p-STAT6 after IL-4 stimulation, p-STAT5 after IL-7 stimulation, and p-STAT3 after IL-21 stimulation (p < 0.001 for FL vs. MCL in all cases). In contrast, receptor-independent signaling was not significantly different as FL tumor infiltrating T cells responded at a level comparable to MCL and DLBCL tumor infiltrating T cells when stimulated with PMA and ionomycin. The lower response to common γ chain family cytokines could be the result of a partial suppression of all tumor infiltrating T cells or a complete suppression of a distinct subset. To distinguish between these possibilities, we analyzed signaling in tumor infiltrating T cell subsets. This single cell approach showed that tumor infiltrating T cells were a heterogeneous mixture of non-responsive cells and highly responsive T cells in response to cytokines. Specifically, the mean percentage of T cells that did not induce p-STAT3 after IL-21 stimulation was 50.3% in FL samples in contrast to only 26.2% in MCL samples. Phenotypic analysis showed that the vast majority of T cells infiltrating FL patient samples were CD4+CD45RO memory cells, and the single cell signaling approach revealed that the FL nonresponsive T cell subset had this phenotype. Furthermore, FL T cells were composed of a significantly larger fraction of T regulatory cells than MCL T cells, on average 17% FoxP3+CD25+ cells compared to only 9% in MCL (p<0.0002). Experiments are ongoing to test whether the prevalence of T regulatory cells influence the signaling capacity of the remaining CD4 conventional T cells. Conclusions: A subpopulation of tumor infiltrating T cells within FL patient samples has reduced responsiveness to the common gamma chain family members IL-4, IL-7 and IL-21, and distinguishes FL from DLBCL and MCL. These results may reflect a more suppressive microenvironment in FL. Disclosures: No relevant conflicts of interest to declare.


Immunity ◽  
2014 ◽  
Vol 41 (6) ◽  
pp. 1026-1039 ◽  
Author(s):  
Peter T. Sage ◽  
Alison M. Paterson ◽  
Scott B. Lovitch ◽  
Arlene H. Sharpe

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2108-2108
Author(s):  
Krzysztof Giannopoulos ◽  
Michael Schmitt ◽  
Paulina Wlasiuk ◽  
Malgorzata Kowal ◽  
Monika Podhorecka ◽  
...  

Abstract Background and Aims: Immunotherapy might represent a novel therapeutical option for patients with B-cell chronic lymphocytic leukemia (B-CLL). Especially patients with limited tumor burden are usually regarded as suitable group for immunotherapy. However the existence of several molecular changes resulting in immunosuppression was reported even in patients with early stages of disease. In current study we assessed the expression of CD25 and FOXP3 in CD4 cells from patients with B-CLL. We also evaluated the influence of immunomodulatory treatment using thalidomide and fludarabine on T regulatory cells (Tregs) population in patients with B-CLL. Methods: Forty B-CLL patients (mean age: 64,1, range: 37 – 79) were evaluated for the expression of CD4, CD25 as well as specific transcription factor FOXP-3 (Forkhead box protein P3) by FACS analysis. Results were compared to those obtained in healthy volunteers (HV). Mixed lymphocyte cell culture with synthetic peptide (MLPC) that correspond to epitope of tumor associated antigen RHAMM, survivin or fibromodulin were perform to assess antitumor T cell reactivity in B-CLL patients. Results: We identified subpopulation of CD4+CD25highFOXP3+ T cells that phenotypically corresponds to Tregs in B-CLL patients. Increased levels of Tregs were observed in B-CLL patients. Significantly higher percentages of Tregs were noted in advanced stages of disease, 11.04% in stage 0-II vs 17.84% in stage III and IV according to Rai classification (Fig1a). No correlation between Tregs percentages and ZAP-70 status was shown, interestingly a tendency to higher percentages in ZAP-70 negative patients was observed 9.9% vs. 13.2%. In 9 CLL patients treated with thalidomide and fludarabine significant reduction of absolute number of circulating Tregs after thalidomide was observed (Fig.1b), in 7 this decrease was enhanced by addition of fludarabine to the treatment. First results from MLPC showed no correlation between specific T cell responses against TAA and presence of T regulatory cells. Conclusion: Increased number of Treg cells in patients with B-CLL suggests that immunosuppression is present in B-CLL patients not only in advanced but also in early stages of disease, and that T cell mediated immune rejection of CLL cell might be hampered by Treg cell. Effective treatment of B-CLL with novel schema combining immunomodulatory drug thalidomide with fludarabine seems to be effective in getting rid of excess of circulating Tregs. Figure 1. A. T regulatory cells in HV and CLL patients in early (0-II) and advanced (III-IV) stage of disease. B. Absolute number of T regulatory cells (CD4+CD25highFOX3+) during thalidomide + fludarabine treatment. Figure 1. A. T regulatory cells in HV and CLL patients in early (0-II) and advanced (III-IV) stage of disease. B. Absolute number of T regulatory cells (CD4+CD25highFOX3+) during thalidomide + fludarabine treatment.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3668-3668
Author(s):  
Tamar Tadmor ◽  
Yu Zhang ◽  
Robert Dunn ◽  
Seung-uon Shin ◽  
Hyung-Mee Cho ◽  
...  

Abstract Abstract 3668 Poster Board III-604 Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T- regulatory cells (‘Tregs’) in a murine tumor model (EMT-6). We compared tumor growth, and the number and function of T- regs cells in wild type immune competent mice ( ICM), B cell deficient mice ( BCDM) and /or in BALB-C mice following B- cell depletion induced by injection of anti murine CD20 antibodies (mCD20 Ab, 18B12, mouse IgG1,k, Biogen-IDEC) Mice were either tumor-naïve or implanted with EMT6 mammary adenocarcinoma cells. Absence of B cells as in BCDM completely inhibited tumor growth in the majority of mice, while B cell depletion in normal mice substantially slowed the growth of EMT-6 tumors compared to wild type mice (ICM). Substantial T regs expansion, as defined by CD4+/CD25+/FOXP3+ cells, was evident on day 26 post tumor inoculation in EMT-6 tumor bearing ICM in comparison to the non- tumor bearing mice ( 15.2 +/− 1.2. % and 11.9 +/− 1.1% respectively), isolated from spleen as compared to naïve or tumor bearing BCDM (10.1+/− 0.2% and 10.8+/− 1.2%) The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes and tumor bed were significantly reduced in the BCDM and/or B cell depleted ICM compared to tumor bearing ICM (10%+/−0.8, 13.9+/− 1.23% and 17+/− 1.3% respectively p<0.01. data from single cell suspensions isolated from spleens on day 20 post tumor inoculation). Similar effects of B cell depletion on the numbers of T-regs were observed in the setting of pre-established EMT6 mammary tumors. In contrast to tumor bearing mice, differences in T-reg number and function were minimal in tumor free B cell deficient or in B cell depleted naïve mice compared to ICM. T-reg function, measured by suppression assay and proliferation assays, was also markedly reduced in tumor bearing BCDM compared to ICM. Combining B cell and T-reg depletion using i.p. injection of anti CD 25 antibody (PC61 or PBS) resulted in similar rates of tumor regression in B cell depleted mice as were seen in BCDM suggesting that the combination of B cells depletion and further depletion of Tregs augmented anti-tumor response. In conclusion, our studies indicate that B cell depletion may play a useful role in augmenting the T cell anti-tumor response, in part due to their effects on T-regulatory cell biology. Disclosures: Dunn: Biogen IDEC: Employment.


Immunology ◽  
2012 ◽  
Vol 135 (4) ◽  
pp. 255-260 ◽  
Author(s):  
Camilla A. Lindqvist ◽  
Angelica S. I. Loskog

Sign in / Sign up

Export Citation Format

Share Document